Alerce Investment Management, L.P.

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Alerce Investment Management, L.P. reported 5 stock positions worth $62.3 million. Its top holding was Annexon (ANNX) at 70.4% of the portfolio, followed by Akebia Therapeutics (AKBA, 12.2%) and Verona Pharma (VRNA, 9.5%). Compared with Q2 2024, it reduced 2. The biggest sale was Whitehawk Therapeutics (WHWK, shares −100%).

Most Recent 13F
Q4 2024
Location
Chicago, IL
CIK
0001844002
Portfolio Value
$62.3M (Q3 2024)
SEC Filing
0000895345-24-000559 ↗ filed Nov 13, 2024

Holdings Value

0$20.0M$40.0M$60.0M$80.0M$100.0M Q1 2024: $95.1M Q1 2024 Q2 2024: $51.0M Q2 2024 Q3 2024: $62.3M $62.3M Q3 2024 Q4 2024: $56.8M Q4 2024

Holdings 5 stocks · $62.3M

ANNX Annexon Inc. 70.35% 7,406,024 $43.8M No change
AKBA Akebia Therapeutics Inc. 12.17% 5,747,906 $7.6M No change
VRNA Verona Pharma Ltd. 9.50% 205,880 $5.9M Reduce -3.3%
AMWL American Well Corp. Class A 7.97% 523,785 $5.0M No change
WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC 0.00% 659 $1K Reduce -100.0%

Portfolio Sells Q2 2024 → Q3 2024

WHWK Whitehawk Therapeutics Inc. Reduce -100.0% 0.00% −4.67
VRNA Verona Pharma Ltd. Reduce -3.3% 9.50% +3.47

Portfolio Buys Q2 2024 → Q3 2024

None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q4 2024 5$56.8MANNX, AKBA, VRNA, AMWL, WHWK
Q3 2024 5$62.3MANNX, AKBA, VRNA, AMWL, WHWK
Q2 2024 5$51.0MANNX, AKBA, AMERICAN WELL CORP, VRNA, WHWK
Q1 2024 5$95.1MANNX, AKBA, AMERICAN WELL CORP, RNTX, WHWK